Chronic Kidney Disease

The introduction and success of direct-acting antivirals drove the Kidney Disease: Improving Global Outcomes work group to make major updates to its clinical practice guidelines regarding hepatitis C virus infection in chronic kidney disease, or CKD.

The American Kidney Fund has announced the creation of a patient engagement program aimed at increasing minority representation in clinical trials.

A published study suggested that a single-item question may help providers better understand the treatment preferences of patients with advanced chronic kidney disease and enable more effective discussions about patient goals.

Evaluation of the association between cardiac biomarkers of myocardial injury, stretch, fibrosis or inflammation and the risk for atrial fibrillation in patients with chronic kidney disease.

The PKD Foundation has launched a new patient registry as part of Polycystic Kidney Disease Awareness Day, held on Sept. 4.

Slower decline in eGFR may be associated with a subsequent lower risk of ESKD, according to a recent random effects meta-analysis of 3,943,212 patients.

Among the top stories in endocrinology last week were the FDA’s decision to fast track the sodium-glucose cotransporter 2 inhibitor dapagliflozin to delay renal failure in patients with or without diabetes who also have with chronic kidney disease and a study that found adults with type 2 diabetes treated with dipeptidyl-peptidase IV inhibitors were more likely to develop pancreatic cancer than those who received other treatment.

Having recently hired its first guideline development director, Kidney Disease: Improving Global Outcomes aims to become more agile in developing and updating guidelines that work for practitioners around the world.

Families of patients who died with advanced chronic kidney disease viewed “aggressive” end-of-life care that focused on life extension less favorably than receipt of palliative care and hospice services, according to a recently published study.

A recently published report found early changes in both albuminuria and eGFR to be effective and reliable end points for use in clinical trials determining chronic kidney disease progression. According to a press release from the National Kidney Foundation, these findings may accelerate clinical trials thereby quickening the approval of new therapies to slow disease progression.